Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | IDH1 | O75874 | 13/20 | 0.44 |
| ▸ | IDH2 | P48735 | 9/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9217242 | 0.89 | LMNA (0.58) | LMNAKMT2AIDH1TGFBR1GRM5 | |
| SCHEMBL16369763 | 0.86 | IDH1 (0.47) | IDH1IDH2 | |
| SCHEMBL2014872 | 0.84 | KMT2A (0.44) | LMNAKMT2AIDH1IDH2TGFBR1 | |
| SCHEMBL8951976 | 0.83 | LMNA (0.70) | LMNAKMT2AGRM5MAPK1 | |
| SCHEMBL31127370 | 0.81 | CCR1 (0.58) | LMNAKMT2AIDH1TGFBR1GRM5 | |
| SCHEMBL2242901 | 0.81 | CCR1 (0.58) | LMNAKMT2AIDH1TGFBR1GRM5 | |
| SCHEMBL9375764 | 0.80 | KMT2A (0.55) | LMNAKMT2ATGFBR1GRM5MAPK1 | |
| SCHEMBL9369412 | 0.80 | LMNA (0.57) | LMNAKMT2AGRM5MAPK1 | |
| SCHEMBL10372073 | 0.79 | LMNA (0.47) | LMNAKMT2ATGFBR1GRM5 | |
| SCHEMBL5480168 | 0.79 | GRM5 (0.61) | LMNAKMT2AGRM5MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144140-A1 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2011-06-16 | — | — | US | disclosed |
| US-20110144140-A1 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2011-06-16 | — | — | US | disclosed |
| US-20110144140-A1 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2011-06-16 | — | — | US | disclosed |
| EP-2066655-A2 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008028935-A2 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008028935-A2 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144140-A1 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS | KCNJ2, KCNN2, KCNN1 | LMNA 2250/4885KMT2A 1374/4885IDH1 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.